Skip to content
2000
Volume 23, Issue 2
  • ISSN: 1570-162X
  • E-ISSN: 1873-4251

Abstract

Background

The increased risk of metabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.

Objective

This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.

Methods

The cross-sectional study was conducted on consecutive patients who visited THE referral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8% male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations between MetS and HIV by the independent variables.

Results

The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (=0.001) and those with more duration since HIV diagnosis (=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54 ± 9.46 kg, 10.91 ± 2.17 kg, 51.31 ± 9.61 kg, and 24.86±10.25% that were higher in MetS group (<0.05).

Conclusion

Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X340090250204072449
2025-02-11
2025-11-06

  • From This Site

    /content/journals/chr/10.2174/011570162X340090250204072449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SaklayenM.G. The global epidemic of the metabolic syndrome.Curr. Hypertens. Rep.20182021210.1007/s11906‑018‑0812‑z 29480368
     [Google Scholar]
  2. CameronA.J. ShawJ.E. ZimmetP.Z. The metabolic syndrome: Prevalence in worldwide populations.Endocrinol. Metab. Clin. North Am.200433235137510.1016/j.ecl.2004.03.005 15158523
     [Google Scholar]
  3. GundoganK. BayramF. GedikV. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults.Arch. Med. Sci.20132224325310.5114/aoms.2013.34560 23671434
     [Google Scholar]
  4. AguilarM. BhuketT. TorresS. LiuB. WongR.J. Prevalence of the metabolic syndrome in the United States, 2003-2012.JAMA2015313191973197410.1001/jama.2015.4260 25988468
     [Google Scholar]
  5. PanW.H. YehW.T. WengL.C. Epidemiology of metabolic syndrome in Asia.Asia Pac. J. Clin. Nutr.200817Suppl. 13742 18296297
     [Google Scholar]
  6. AziziF. KhaliliD. AghajaniH. Appropriate waist circumference cut-off points among Iranian adults: The first report of the Iranian National committee of obesity.Arch. Iran Med.2010133243244 20433230
     [Google Scholar]
  7. SadrbafoghiS.M. SalariM. RafieeM. Prevalence and criteria of metabolic syndrome in an urban population: Yazd Healthy Heart Project (article) Author.Tehran Univ. Med. J.200664109096
     [Google Scholar]
  8. ShahbazianM. JacobsR. WyattJ. Validation of the cone beam computed tomography–based stereolithographic surgical guide aiding autotransplantation of teeth: Clinical case–control study.Oral Surg. Oral Med. Oral Pathol. Oral Radiol.2013115566767510.1016/j.oooo.2013.01.025 23601222
     [Google Scholar]
  9. GovenderR.D. HashimM.J. KhanM.A.B. MustafaH. KhanG. Global epidemiology of HIV/AIDS: A resurgence in North America and Europe.J. Epidemiol. Glob. Health202111329630110.2991/jegh.k.210621.001 34270183
     [Google Scholar]
  10. The Global HIV/AIDS Epidemic2024 Available from: https://www.kff.org/global-health-policy/fact-sheet/the-global-hiv-aids-epidemic/
  11. ChhounP. TuotS. HarriesA.D. KyawN.T.T. PalK. MunP. High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia.PLoS One20171211e018759110.1371/journal.pone.0187591
     [Google Scholar]
  12. HyleE.P. NaidooK. SuA.E. El-SadrW.M. FreedbergK.A. HIV, tuberculosis, and noncommunicable diseases: What is known about the costs, effects, and cost-effectiveness of integrated care?J. Acquir. Immune Defic. Syndr.201467Suppl. 1S87S95
     [Google Scholar]
  13. JonesC.Y. Metabolic syndrome in HIV-infected patients: No different than the general population?Clin. Infect. Dis.200744573573810.1086/511691 17278069
     [Google Scholar]
  14. FreitasP. CarvalhoD. SoutoS. Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.BMC Infect. Dis.201111124610.1186/1471‑2334‑11‑246 21933422
     [Google Scholar]
  15. AlvarezC. SalazarR. GalindezJ. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America.Braz. J. Infect. Dis.201014325626310.1016/S1413‑8670(10)70053‑2 20835509
     [Google Scholar]
  16. BoshoD.D. DubeL. MegaT.A. AdareD.A. TesfayeM.G. EshetieT.C. Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV).Diabetol. Metab. Syndr.20181011010.1186/s13098‑018‑0312‑y 29483948
     [Google Scholar]
  17. NguyenK.A. PeerN. MillsE.J. KengneA.P. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population.PLoS One2016113e0150970
     [Google Scholar]
  18. MondyK. OvertonE.T. GrubbJ. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.Clin. Infect. Dis.200744572673410.1086/511679 17278068
     [Google Scholar]
  19. SeyedAlinaghi S. HIV in Iran: onset, responses, and future directions.AIDS2021354529542
     [Google Scholar]
  20. ShakibaM. ShokouhiS. AlaeiF. KeyvanfarA. NajafiarabH. YasaeiM. Prevalence of dysglycemia, dyslipidemia, and metabolic syndrome among patients with HIV infection: A cross-sectional study from Iran.Med. J. Islam. Repub. Iran202337115
     [Google Scholar]
  21. DavoodianP. NourozianM. The prevalence of metabolic and endocrine disorders among HIV-infected patients in a population from the South of Iran.Dis Diagn202211139
     [Google Scholar]
  22. Evaluation and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP).JAMA20012852486249610.1001/jama.285.19.2486 11368702
     [Google Scholar]
  23. GrundyS.M. CleemanJ.I. DanielsS.R. Diagnosis and management of the metabolic syndrome: An American Heart Association/National heart, lung, and blood institute scientific statement.Circulation20051121727352752
     [Google Scholar]
  24. KwiatkowskaW. KnyszB. Drelichowska-DurawaJ. Subclinical carotid atherosclerosis and cardiovascular risk factors in HIV-infected patients.Postepy Hig. Med. Dosw.20116577078310.5604/17322693.967075 22173442
     [Google Scholar]
  25. JericóC. KnobelH. MonteroM. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors.Diabetes Care200528113213710.2337/diacare.28.1.132 15616246
     [Google Scholar]
  26. EstradaV. Martínez-LarradM.T. González-SánchezJ.L. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy.Metabolism200655794094510.1016/j.metabol.2006.02.024 16784968
     [Google Scholar]
  27. SamarasK. WandH. LawM. EmeryS. CooperD. CarrA. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia.Diabetes Care200730111311910.2337/dc06‑1075 17192343
     [Google Scholar]
  28. MartinL.S. PasquierE. RoudautN. Metabolic syndrome: A major risk factor for atherosclerosis in HIV-infected patients (SHIVA study).Presse Med.200837457958410.1016/j.lpm.2007.09.022 18313892
     [Google Scholar]
  29. YuhanaM.Y. KamarulzamanA. PendekR. IsmailN. The prevalence and characteristics of metabolic syndrome in urban Malaysian HIV-infected patients.Int. J. Infect. Dis.201216e19510.1016/j.ijid.2012.05.768
     [Google Scholar]
  30. AyodeleO.E. AkinboroA.O. AkinyemiS.O. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome.Metab. Syndr. Relat. Disord.201210537337910.1089/met.2012.0050 22799758
     [Google Scholar]
  31. WormS.W. LundgrenJ.D. The metabolic syndrome in HIV.Best Pract. Res. Clin. Endocrinol. Metab.201125347948610.1016/j.beem.2010.10.018 21663841
     [Google Scholar]
  32. van WijkJ.P.H. CabezasM.C. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: Effects of antiretroviral therapy and adipose tissue distribution.Int. J. Vasc. Med.2012201211310.1155/2012/201027 21876813
     [Google Scholar]
  33. SearsS. BuendiaJ.R. OdemS. Metabolic syndrome among people living with HIV receiving medical care in Southern United States: Prevalence and risk factors.AIDS Behav.201923112916292510.1007/s10461‑019‑02487‑8 30929149
     [Google Scholar]
  34. TodowedeO.O. MiandaS.Z. SartoriusB. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa—a systematic review and meta-analysis.Syst. Rev.201981410.1186/s13643‑018‑0927‑y 30606249
     [Google Scholar]
  35. OjongE. IyaB. DjeufouataJ. Metabolic syndrome and its components among HIV/AIDS patients on antiretroviral therapy and ART-Naïve patients at the University of Calabar Teaching Hospital, Calabar, Nigeria.Afr. Health Sci.202222141041710.4314/ahs.v22i1.50 36032434
     [Google Scholar]
  36. MazloomzadehS. Rashidi KhazaghiZ. MousavinasabN. The prevalence of metabolic syndrome in Iran: A systematic review and meta-analysis.Iran. J. Public Health2018474473480 29900131
     [Google Scholar]
  37. AssefaA. AbiyeA.A. TadesseT.A. WolduM. Prevalence and factors associated with dyslipidemia among people living with HIV/AIDS on follow-up care at a tertiary care hospital in Ethiopia: A cross-sectional study.Drug Healthc. Patient Saf.2023159310210.2147/DHPS.S395037 37546170
     [Google Scholar]
  38. MuyanjaD. High prevalence of metabolic syndrome and cardiovascular disease risk among people with HIV on stable ART in Southwestern uganda.AIDS Patient Care STDS201630141010.1089/apc.2015.0213
     [Google Scholar]
  39. MøllerS.P. AmareH. ChristensenD.L. HIV and metabolic syndrome in an Ethiopian population.Ann. Hum. Biol.202047545746410.1080/03014460.2020.1781929 32683894
     [Google Scholar]
  40. KajogooV.D. Gorret AtimM. AmareD. HIV protease inhibitors and insulin sensitivity: A systematic review and meta-analysis of randomized controlled trials.Front. Pharmacol.20211263508910.3389/fphar.2021.635089 34790115
     [Google Scholar]
  41. KajogooV.D. AmogneW. MedhinG. New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis.Metabol. Open20231710023510.1016/j.metop.2023.100235
     [Google Scholar]
  42. ShahS. HillA. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.Curr. Opin. Infect. Dis.2021341162410.1097/QCO.0000000000000695 33278177
     [Google Scholar]
  43. Crum-CianfloneN. RoedigerM.P. EberlyL. HeaddM. MarconiV. GanesanA. Increasing rates of obesity among HIV-infected persons during the HIV epidemic.PLoS One201054e10106
     [Google Scholar]
  44. NaluggaE.A. LakerE. NabaggalaM.S. Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda.BMC Nutr.20228110710.1186/s40795‑022‑00604‑w 36167612
     [Google Scholar]
  45. Chițu-TișuC.E. BarbuE.C. LazărM. Body composition in HIV-infected patients receiving highly active antiretroviral therapy.Acta Clin. Belg.2017721556210.1080/17843286.2016.1240426 27724840
     [Google Scholar]
  46. AurpibulL. NamwongpromS. SudjaritrukT. OunjaijeanS. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment.PLoS One2020153e023070710.1371/journal.pone.0230707
     [Google Scholar]
/content/journals/chr/10.2174/011570162X340090250204072449
Loading
Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV
Cur. HIV Res. 23, 77 (2025); https://doi.org/10.2174/011570162X340090250204072449
/content/journals/chr/10.2174/011570162X340090250204072449
/content/journals/chr/10.2174/011570162X340090250204072449
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): abdominal obesity; AIDS; HIV; Metabolic syndrome; obesity; waist circumference

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test